Detect early Parkinson brain changes
- Trial ID
- NCT04101968
- Official Title
- Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers
- Goal
- Detect early Parkinson brain changes
- Status
- RECRUITING
- Sponsor
- Pacific Parkinson's Research Centre
- Study Type
- OBSERVATIONAL
- Enrollment
- 25 participants
- Conditions
- Parkinson Disease, GBA Gene Mutation, Gaucher Disease
- Interventions
- PET scan, neuroQWERTY
Plain-Language Summary
Goal: to spot molecular and digital markers that distinguish people with Parkinson's who carry a GBA gene mutation from carriers who have no symptoms, to better understand early or GBA-specific brain changes. Approach: participants have PET scans to image molecular brain changes, for example dopamine system integrity or metabolic and inflammatory signals, and use neuroQWERTY, a keystroke and smartphone-based biometric tool that analyzes typing and movement patterns for subtle motor and cognitive signs; some PD participants may need brief medication withdrawal for the imaging, while the digital measures work without changing medications. Eligibility: adults 18 to 80 who are heterozygous for a pathogenic GBA mutation or polymorphism can join, while people with other neurological disorders, MRI-unsafe implants, severe claustrophobia, inability to tolerate stopping antiparkinsonian meds, or current cholinergic drug treatment are excluded.
Locations
- Oregon Health & Science University, Portland, Oregon, United States
- University of Washington, Seattle, Washington, United States
- Pacific Parkinson's Research Centre | University of British Columbia, Vancouver, British Columbia, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PET scan. Goal: to spot molecular and digital markers that distinguish people with Parkinson's who carry a GBA gene mutation from carriers who have no symptoms, to better understand early or GBA-specific brain changes. Approach: participants have PET scans to image molecular brain changes, for example dopamine system integrity or metabolic and inflammatory signals, and use neuroQWERTY, a keystroke and smartphone-based biometric tool that analyzes typing and movement patterns for subtle motor and cognitive signs; some PD participants may need brief medication withdrawal for the imaging, while the digital measures work without changing medications. Eligibility: adults 18 to 80 who are heterozygous for a pathogenic GBA mutation or polymorphism can join, while people with other neurological disorders, MRI-unsafe implants, severe claustrophobia, inability to tolerate stopping antiparkinsonian meds, or current cholinergic drug treatment are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 6 years and 8 months.